Correspondence to "Escape Velocity-The Launch of Microbiome Therapies"
- PMID: 39565899
- PMCID: PMC12486162
- DOI: 10.1093/infdis/jiae575
Correspondence to "Escape Velocity-The Launch of Microbiome Therapies"
Conflict of interest statement
Potential conflicts of interest. B. O. is an employee of, and owns stock options of, Vedanta Biosciences, Inc. Both other authors report no potential conflicts. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment in
-
Reply to Olle et al.J Infect Dis. 2025 Feb 20;231(2):545. doi: 10.1093/infdis/jiae576. J Infect Dis. 2025. PMID: 39560137 No abstract available.
Comment on
-
Reply to Olle et al.J Infect Dis. 2025 Feb 20;231(2):545. doi: 10.1093/infdis/jiae576. J Infect Dis. 2025. PMID: 39560137 No abstract available.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
